The griffithsin and carrageenan combination is a promising candidate to prevent or treat infections by SARS-CoV-1 and SARS-CoV-2. Carrageenan and griffithsin combinations exhibited synergistic activity (EC_50 between 0.2 and 3.8 µg/mL combination index < 1), including against recent SARS-CoV-2 mutations. Iota and lambda carrageenan showed the most potent antiviral activity (EC50 between 3.2 and 7.5 µg/mL).
Calcusyn synergism software#
The potential synergistic, additive, or antagonistic effect of different compound combinations was determined by CalcuSyn v1 software (Biosoft, Cambridge, UK), which estimated the combination index (CI) values. Subcutaneous (s.c) and orthotopic BSTS models were obtained in NOD/SCID mice and tumor growth was. The therapeutic index (TI = CC_50/EC_50) was calculated for each compound. Drug synergism was evaluated by Calcusyn software. In brief, CI values between 0.9 and 0.85 would suggest a moderate synergy, whereas those in the range of 0.7 to 0.3 are indicative of clear synergistic interactions. Based on CI values, the extent of synergism/antagonism may be determined. Synergy was defined based on terminology of Chou. Synergism is achieved for these combinations when the experimentally. Calcusyn software defines synergy when CI value is < 1. The half-maximal cytotoxic concentration (CC_50) and half-maximal effective concentration (EC50) were determined for each compound, using a dose-response-inhibition analysis on GraphPad Prism v9.0.2 software (San Diego, CA, USA). Software packages CalcuSyn (also available as CompuSyn) and Combenefit are designed. We evaluated the antiviral selectivity of griffithsin and sulfated and non-sulfated polysaccharides against SARS-CoV-1 and SARS-CoV-2 using a cytotoxicity assay and a cell-based pseudoviral model.
![calcusyn synergism calcusyn synergism](https://www.researchgate.net/profile/Pei-Hsin-Cheng/publication/256983015/figure/fig6/AS:196101085896718@1423765550583/Analysis-by-Calcusyn-Biosoft-Ferguson-MO-of-the-interaction-between-rapamycin-and.png)
It is essential to identify broad-spectrum antiviral agents that may prevent or treat infections by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) but also by other coronaviruses that may jump the species barrier in the future. we systematically tested the synergy, additivity or antag-onism of combinations of protease, NS5A and nucleotide NS5B inhibitor classes as well as the combination of these DAAs with host-targeting agent cyclosporin A or non-antibody entry inhibitor (S)-chlorcyclizine.
![calcusyn synergism calcusyn synergism](https://f6publishing.blob.core.windows.net/d9100f8a-1072-4a87-a0f0-3a3fc04399dd/WJG-14-1491-g004.jpg)
In order to determine whether the combination of NVP-AEW541 and trastuzumab was additive, antagonist, or. Over 182 million confirmed cases of COVID-19 and more than 4 million deaths have been reported to date around the world. analyses of synergism by the CalcuSyn program.